Gujarat Themis Biosyn Attracts Attention Following Rs 1,300 Crore Acquisition Deal with Japanese Entity
Gujarat Themis Biosyn Set to Acquire Majority Stake in MicroBiopharm Japan
Gujarat Themis Biosyn shares are likely to remain in focus on May 25, 2026, after the company announced the acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd., a Japan-based company with more than six decades of expertise in fermentation, microbial-based research, development, and manufacturing of pharmaceuticals and specialty chemicals.
The acquisition is expected to be completed during the second quarter of financial year 2027, subject to customary regulatory approvals and closing conditions. The total acquisition cost stands at JPY 21.5 billion (approximately ₹1,300 crore) and will be financed through an optimal combination of debt and equity.
MicroBiopharm Japan's acquisition is a strategic move by Gujarat Themis Biosyn to expand its capabilities in the pharmaceutical and specialty chemicals sector.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Meanwhile, the board of directors of Gujarat Themis Biosyn is scheduled to meet on May 25, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend on the company's equity shares for FY26, if any.
In the previous trading session, the share closed at Rs 368.85, up Rs 11.75, or 3.29 percent. The share touched a 52-week high of Rs 479.45 and a 52-week low of Rs 225.75 on October 27, 2025, and March 30, 2026, respectively. Currently, the stock is trading 23.07 percent below its 52-week high and 63.39 percent above its 52-week low.
The market capitalisation of the company stands at Rs 4,019.18 crore.
| FY26 Q1 | |
|---|---|
| Gujarat Themis Biosyn | |
| MicroBiopharm Japan | (Acquisition details not provided) |
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Note: The comparison table is not applicable in this case as the data for MicroBiopharm Japan is not provided.
Investor Takeaway
Investors should keep an eye on Gujarat Themis Biosyn's stock as it may see a positive impact from the acquisition deal.
More in Market
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Indian Stocks to Watch: BHEL, Agarwal Industrial, JBM Auto, Rajesh Exports, Indian Energy Exchange, Lenskart Solutions in Market Focus on June 4.
